Eyenovia (NASDAQ:EYEN) will announce its earnings results before the market opens on Tuesday, November 13th. Analysts expect the company to announce earnings of ($0.42) per share for the quarter.

Eyenovia (NASDAQ:EYEN) last announced its quarterly earnings results on Tuesday, August 14th. The company reported ($0.33) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.09. On average, analysts expect Eyenovia to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ EYEN opened at $3.96 on Friday. The firm has a market capitalization of $39.37 million and a PE ratio of -1.81. Eyenovia has a fifty-two week low of $2.94 and a fifty-two week high of $10.74.

Several equities analysts have recently weighed in on EYEN shares. HC Wainwright started coverage on Eyenovia in a research report on Tuesday, October 9th. They issued a “buy” rating and a $12.00 price target for the company. Zacks Investment Research cut Eyenovia from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Finally, ValuEngine upgraded Eyenovia from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Eyenovia presently has a consensus rating of “Buy” and an average price target of $18.31.

COPYRIGHT VIOLATION WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/eyenovia-eyen-scheduled-to-post-earnings-on-tuesday/2599175.html.

Eyenovia Company Profile

Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.

See Also: Float

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.